Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations.
published in: The Journal of Allergy and Clinical Immunology
date of publication: 2017-10-27
language: English
main subject: ruxolitinib
Cites articles 66
- 2013-09-01
Date
Title
Article - wd:Q47588428